Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Does Novartis AG (NVS) Have The Solution For Malaria?

Results for a potentially game-changing proof of concept study were just published concerning malaria by Novartis AG (NYSE:NVS) in the New England Journal of Medicine. The results show that KAF156, a new antimalarial compound, has demonstrated activity in opposition to both falciparum and vivax malaria and artemisinin-resistant parasites.

Malaria, A Life Threatening Disease

Malaria is a mosquito-borne life-threatening disease caused primarily by the parasites plasmodium falciparum and plasmodium vivax. The disease affects humans and other animals caused by parasitic protozoans, transmitted to humans through the bites of mosquitoes infected by anopheles. The symptoms usually begin 10 to 15 days after being bitten. If not treated properly, those who have incurred the disease may have recurrences after a few months. Nearly half a million people, primarily children, die of the disease every year.

Highest Paid Medical Technicians in America

Natee K Jindakum/

Coartem, a kind of artemisinin-based combination therapy (ACT), is primarily used and is currently the standard of care to help fight falciparum infections. Consequently, the growing resistance to artemisinin and weakening partner drug efficacy in Southeast Asia is weakening global control of plasmodium falciparum malaria. This is the reason why pharmaceutical companies need to manufacture new drugs for the disease.

KAF156: A Potential Revolutionary Therapy To Fight Malaria

KAF156 is the first compound from a novel class of drugs called imidazole piperazines. The said compound’s action mechanism is still being characterized but is foreseen to be related to a gene that was previously uncharacterized. This gene is said to be called Plasmodium falciparum cyclic amine resistance locus, Pfcarl. KAF156 could soon become a component of a combination regimen that will be used to treat malaria. This is in line with the guidance of WHO wherein antimalarials be co-formulated to mitigate the risk of parasite resistance development.

A phase II, open-label, two-part study was conducted in five centers in Vietnam and Thailand from March until August 2013. The study was conducted to assess KAF156 in adult patients who have malaria. The study conducted used 10 patients who have p. falciparium malaria and 11 patients who have p. vivax malaria.

Follow Novartis A G (NYSE:NVS)
Trade (NYSE:NVS) Now!
Note: This article is written by Andy Parker and was originally published at Market Exclusive.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.